Overeating Part 2: GLP-1 Side Effects from Pub-Med & Clinically Reviewed Trials

In this episode of the Prep Life Podcast, hosts Amy Inger and Leigh Marie Jones continue their deep dive into the science of overeating with a focus on the clinically documented side effects of GLP-1 receptor agonists like semaglutide (Ozempic), tirzepatide (Mounjaro), and the emerging GLP-3 drug retatrutide. Drawing from peer-reviewed trials, meta-analyses, and NEJM phase 2 and 3 studies, they break down the most common adverse effects—primarily gastrointestinal (nausea, vomiting, diarrhea, constipation), dose-dependent increases in heart rate, injection site hypersensitivity, and a newly emerging neurological side effect: abnormal skin sensations (dysesthesia) linked to retatrutide. They also discuss the clinically significant risk of excessive weight loss, malnutrition, and muscle loss (sarcopenia), especially in populations not prioritizing protein intake or resistance training. A particularly compelling point is the potential for anhedonia—loss of pleasure—due to the drugs' blunting of the brain’s reward system, though this may paradoxically help with addiction cessation. The hosts emphasize that while these drugs are powerful, they are not without trade-offs, and long-term safety data remains limited. They caution against self-titration, black-market sourcing, and misuse, especially in natural bodybuilding competitions where such medications disqualify athletes.